Amprius Prices Warrants, Not Orders

The Setup

Amprius Technologies (AMPX) is a U.S.-listed silicon-anode battery company whose stock is still being priced like a capital-structure cleanup story. That is stale.

The current tape is no longer just a warrant-overhang tape. The company reported Q1 2026 revenue of $28.5 million, up 153% year over year, flipped gross margin to 20%, raised 2026 revenue guidance to at least $130 million, and then priced an exchange of 7,128,458 public warrants into 2,726,631 common shares, 62% fewer shares than physical exercise would have created. The stock closed at $20.28 on May 29, 2026, with 8,755,624 shares traded, according to Stooq data pulled at 12:03 ICT on June 1, 2026.

The mispricing is narrow but tradable: the market still treats AMPX as a dilution and SPAC-warrant cleanup, while the most recent primary-source evidence says the warrant overhang has been partly converted into known dilution just as revenue, defense demand, and short interest are pressing in the other direction.

Opportunity Ranking

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Near-Term >5% Move Case	Asymmetry	Main Reason to Reject
1	Long `AMPX`, Amprius Technologies	U.S. battery equity / warrant overhang / short-interest squeeze	The stock is still digesting public-warrant dilution after the exchange, but Q1 revenue, margin, guidance, and defense-order evidence improved at the same time.	May 6 Q1 release, May 14 warrant pricing release, April 30 short-interest data, May 29 Stooq close.	Days to weeks: post-exchange float digestion, June short-interest update, follow-through from May investor events and defense/customer-order narrative.	A move from $20.28 to $21.50 to $22.50 is a 6% to 11% advance if shorts reduce exposure after warrant mechanics are known or if buyers re-anchor on raised 2026 revenue guidance.	Defined invalidation near $17.80 to $18.00 versus upside toward the April short-interest report price zone above $21 and a top case near $25.	Selected. Main risk is that the remaining warrant stack and valuation already price the revenue ramp.
2	Long `PCRX`, Pacira BioSciences	U.S. biopharma / proxy contest / activist catalyst	DOMA's proxy contest creates a dated June 9 annual-meeting catalyst around strategy, sale optionality, and board composition.	Pacira definitive proxy and DOMA proxy materials from April and May 2026; May 29 Stooq close at $23.22.	June 9, 2026 annual meeting.	A proxy surprise or settlement could move the stock more than 5%, but the same event can also raise execution and litigation risk.	Possible upside if governance pressure forces a credible sale process.	Rejected because the prior desk screens already flagged PCRX as a messy catalyst where the activist cure may be worse than the disease.
3	Long `ENSC`, Ensysce Biosciences	U.S. microcap biotech / strategic alternatives	A formal strategic-review process can create upside from partnerships, licensing, asset sales, or capital formation.	February 25 strategic-review release; May 29 Stooq close at $0.281.	Unspecified strategic-review process.	Any partnership headline can move a sub-$1 biotech more than 5%, but evidence quality is weak and financing risk is severe.	High headline convexity.	Rejected because there is no dated catalyst, liquidity is fragile, and the setup risks becoming a financing trade rather than a mispricing.

Selected opportunity: Long AMPX common stock.

Why this one now: The short-interest and warrant-overhang evidence is current, the Q1 operating evidence is primary-source, and the trade has a near-term path that does not require a takeover, clinical readout, or court decision.

Why it can jump more than 5% soon: A close above $21.30 to $21.50 only requires AMPX to reclaim the April 30 short-interest reference price zone. That is a 5% to 6% move from the May 29 close. The trigger can be mechanical rather than heroic: short-covering after known warrant dilution, a cleaner share-count debate, or a re-rating of raised 2026 guidance.

What should surprise the reader: The bearish dilution story is no longer open-ended. The company turned 7.1 million public warrants into 2.7 million shares and described the issuance as 62% fewer shares than physical exercise. That does not remove all dilution risk, but it changes the argument from "unknown warrant wall" to "known dilution against improving revenue."

The Mispricing

The market appears to be pricing AMPX as a story stock with SPAC debris still hanging over the cap table. That is not wrong. The public warrants came from the old Kensington SPAC structure, are exercisable at $11.50, and were not scheduled to expire until September 2027. A clean stock should not need repeated warrant cleanup.

The variant view is more precise: the market is over-weighting the recent warrant headline and under-weighting the fact that the exchange fixed a large part of the dilution math at a known share count while the business inflected.

Facts:

AMPX closed at $20.28 on May 29, 2026, after trading between $19.16 and $20.78 that day, according to Stooq.
On May 14, Amprius said it would issue 2,726,631 shares for 7,128,458 public warrants, 62% fewer shares than physical exercise of those warrants.
On May 6, Amprius reported Q1 2026 revenue of $28.5 million, gross profit of $5.7 million, 20% gross margin, GAAP net loss of $5.0 million, and adjusted EBITDA loss of $1.8 million.
The company raised 2026 revenue guidance to at least $130 million.
MarketBeat reported April 30 short interest of 23,225,858 shares, 17.86% of float, up 7.77% from the prior report, with 2.7 days to cover.

Inference:

The bearish side had a defensible reason to press the stock while the warrant exchange was being priced. That reason weakens after the exchange terms are known. The short base is still large enough that a shift from dilution fear to revenue validation can move price faster than a normal fundamental re-rate.

Speculation:

Some of the short interest may have been warrant hedging or event-driven inventory tied to the exchange. The public data does not prove that composition. The trade does not require all shorts to be hedged warrant holders, but it does require enough of the short base to be sensitive to cleaner capital-structure evidence.

Price

AMPX is trading as a high-beta growth equity, not as a cheap battery manufacturer. That matters. At $20.28 and roughly 141.6 million shares outstanding in the MarketBeat short-interest table, the equity value is near $2.9 billion before adjusting for remaining warrants, options, and balance-sheet items. Against guidance of at least $130 million of 2026 revenue, the stock already embeds a large multiple.

That is why the long thesis is not "AMPX is cheap." It is that the next 5% to 20% move can be driven by a better technical and narrative setup after the warrant exchange, not by a settled discounted-cash-flow case.

The relevant price markers:

Marker	Level	Why It Matters
May 29, 2026 close	$20.28	Latest Stooq close used for this article.
May 29 intraday low	$19.16	First failure level if the post-exchange bid fades.
$18.00 area	About 11% below close	Psychological and warrant-redemption reference zone discussed in historical warrant documents and retail commentary. Use as thesis-damage zone, not a hard legal trigger in this article.
$21.10	April 30 short-interest report price in MarketBeat table	Reclaiming this zone would pressure shorts marked from the latest reported short-interest date.
$22.50 to $25.00	Base-to-top target zone	Requires either short covering or investors to treat the Q1 guidance raise as more important than warrant dilution.

Positioning

Positioning is the heart of the trade.

MarketBeat's April 30 short-interest snapshot shows 23.23 million shares sold short, equal to 17.86% of float, with 2.7 days to cover. That is high enough to matter, but not so high that the thesis should be sold as a pure squeeze. The more useful point is that the short base grew while the warrant exchange and Q1 debate were live. If part of that short base was tied to warrant hedging, the incentive set changes once the exchange ratio is fixed and the closing window passes.

What is supported:

Short interest was elevated and rising as of April 30.
The company had a live public-warrant exchange in May.
The exchange reduced the number of shares issued relative to physical exercise of those specific warrants.

What is not proven:

The exact fraction of short interest tied to warrant hedging.
Current borrow cost.
Current option skew, dealer gamma, or live intraday short-covering.

The positioning claim is therefore conditional: AMPX is long only if the market is still carrying short exposure built around a dilution event whose worst near-term share-count uncertainty has narrowed.

Catalyst

The catalyst path is not one clean date. It is a stack of near-term recognition events:

Known dilution replaces unknown dilution. The May 14 warrant-pricing release fixed the exchange at 2,726,631 shares for 7,128,458 public warrants.
Short-interest update risk. The next exchange-reported short-interest data can show whether the bearish base is reducing after the exchange. A decline would support the thesis; another increase would weaken it.
Revenue-guidance follow-through. Q1 revenue was $28.5 million and 2026 guidance was raised to at least $130 million. The burden now shifts to purchase-order conversion and margin durability.
Defense and mobility demand narrative. Amprius cited approximately $500 million of new orders awarded to longstanding U.S. defense customers across military branches, plus a $21 million light-electric-vehicle purchase order. Those are not the same as booked AMPX revenue, but they support the demand pipeline.

The closing mechanism is reclassification. The stock does not need a new miracle. It needs investors to stop treating the May tape as only warrant dilution and start treating it as warrant cleanup plus revenue acceleration.

Payoff Map

The trade expression is long common stock, sized as a tactical event trade rather than a core compounder. The company is still loss-making on a GAAP basis, dilution is not gone, and a $2 billion-plus equity value leaves no margin for narrative laziness.

The base case is a move to $22.50 over several weeks as the stock clears the $21.10 short-interest reference price and investors re-anchor on the revenue guide. The top case is $25.00 if short covering and defense-demand follow-through overlap. The bottom case is $17.00 if the market decides the exchange only pulled dilution forward, the remaining warrant/valuation debate reopens, or the stock loses the May post-exchange bid.

Price Target and Probability Map

Scenario	Target Price	Probability	Return From $20.28	Contribution to Expected Return	Evidence Quality	What Has To Happen
Top case	$25.00	25%	23.3%	5.8%	Medium	Shorts reduce exposure, the market treats the exchange as cleanup rather than dilution, and defense/customer-order evidence supports the raised revenue guide.
Base case	$22.50	45%	10.9%	4.9%	Medium-high	AMPX reclaims the April 30 short-interest reference zone near $21.10 and buyers price a cleaner near-term cap table.
Bottom case	$17.00	30%	-16.2%	-4.9%	Medium	Remaining warrant risk, valuation compression, or growth-stock weakness overwhelms the cleanup narrative.

Probability-weighted expected return: about +5.8% before trading costs, slippage, taxes, borrow effects if hedged, and gap risk. That is good enough for a tactical long, not good enough for a blind high-conviction position.

What Would Prove This Wrong

The thesis breaks if AMPX trades below $18.00 on volume without a market-wide growth selloff. That would imply the post-exchange cleanup is not drawing real buyers.

It also breaks if the next short-interest update shows shorts still rising materially after the warrant exchange, because the "event-driven short exposure can relax" part of the thesis would be wrong.

Fundamentally, the trade should be revisited if management walks back revenue guidance, if gross margin slips back toward negative territory, or if new financing resets the dilution debate. AMPX cannot be valued like a clean growth company while behaving like a serial capital-structure repair.

Risk Audit

Strongest counterargument: AMPX is not cheap. Even after real Q1 progress, the equity value already discounts a steep revenue ramp. The warrant exchange may be less a cleanup catalyst than a reminder that the stock still carries SPAC-era dilution architecture.

Most fragile assumption: The short base is at least partly event-sensitive and will care that the exchange ratio is fixed. Public short-interest data does not identify hedged warrant holders.

What the market may already know: The May 14 release plainly stated the exchange ratio and the 62% fewer-share comparison. The stock may already have absorbed the cleanup argument.

What could make the trade lose money even if the thesis is directionally right: A broad selloff in high-multiple growth equities can swamp a company-specific cleanup. A buyer can be right that dilution uncertainty fell and still lose money if the multiple compresses.

Liquidity / execution risks: AMPX traded 8.76 million shares on May 29, but volatility is high. Use limit orders. Avoid chasing an opening gap.

Leverage risks: Do not lever this setup. The bottom case is not theoretical.

Information reliability risks: The revenue and warrant data come from company releases and filings. Short-interest data is delayed and does not reveal holder motives.

Invalidation trigger: A daily close below $18.00 on company-specific weakness, or a fresh filing that reopens material equity-supply risk.

Publish / revise / reject recommendation: Publish as a tactical long common-stock note, not as a long-term valuation deep dive.

Best Trade Strategy

Direction: Long.

Preferred instrument: AMPX common stock.

Common-stock stance: Buy only near the May 29 reference price zone, not after a vertical gap. A practical entry band is $19.50 to $20.75, using $20.28 as the article reference close.

Options stance: Options may exist, but this article does not use them as the preferred expression because live option-chain liquidity, spread width, and skew were not verified during this run. Options execution status: insufficient live data. Required data before using calls or call spreads: current chain, open interest, bid-ask width, implied volatility, and event calendar.

Take-profit: First trim near $22.50. Reassess near $25.00 rather than assuming a squeeze extends.

Stop loss / invalidation: Treat a company-specific close below $18.00 as thesis damage. A tighter risk manager can use $19.10, just below the May 29 intraday low, but that risks being shaken out by normal AMPX volatility.

Time horizon: Two to six weeks.

Execution risks: High volatility, growth-equity beta, delayed short-interest data, remaining warrant uncertainty, and valuation compression.

Do-not-trade conditions: Do not buy if the stock gaps above $22.50 before entry, if a new financing is announced, if the next short-interest update shows a material increase after the exchange, or if management guidance changes before entry.

Monitoring checklist:

Next exchange-reported short-interest update.
Any AMPX filing that updates shares outstanding, warrants, or financing plans.
Customer-order conversion evidence, especially defense and mobility channels.
Gross-margin durability in the next quarterly update.
Whether price holds above $19.16 and then reclaims $21.10.

Bottom Line

AMPX is not a cheap stock. It is a cleaner event trade than the market is giving it credit for. The long case is that a known 2.7 million-share warrant exchange, rising revenue guidance, and elevated short interest create a better near-term setup than the stale "SPAC dilution" label implies. The trade is long common stock, tactical, and invalid below $18.00.

Research Quality Scorecard

Criterion	Score	Rationale
Market disagreement	5	Clear tension between warrant-overhang pricing and improving revenue/gross-margin evidence.
Evidence base	5	Uses current price data, company releases, SEC-linked warrant evidence, and short-interest data.
Positioning and flows	4	Short interest is well evidenced, but the exact warrant-hedge component is unproven.
Catalyst path	4	Warrant exchange, short-interest updates, and guidance recognition are observable, though not one binary date.
Payoff architecture	4	Targets, probabilities, EV, and invalidation are explicit.
Invalidation discipline	5	Clear price and data triggers are included.
Differentiated insight	4	The non-obvious angle is known dilution plus operating inflection, not a generic battery bull story.
Client value	5	Useful as a tactical setup even if no trade is taken.
Total	36 / 40	Publishable Deep Dive Trade Note.

Sources

Source	Date / Timestamp	Use
Stooq daily quote CSV for `AMPX.US`, pulled June 1, 2026 at 12:03 ICT, `https://stooq.com/q/l/?s=ampx.us&i=d`	May 29, 2026 market close	Current article reference price, intraday range, and volume.
Amprius, "Amprius Technologies Announces the Pricing of its Previously Announced Exchange of Public Warrants for Common Stock," `https://ir.amprius.com/news-events/press-releases/detail/167/amprius-technologies-announces-the-pricing-of-its-previously-announced-exchange-of-public-warrants-for-common-stock`	May 14, 2026	2,726,631 shares for 7,128,458 public warrants; 62% fewer shares than physical exercise; expected May 18 closing.
Amprius, "Amprius Technologies to Simplify Capital Structure Through Exchange of Public Warrants for Common Stock," `https://ir.amprius.com/news-events/press-releases/detail/166/amprius-technologies-to-simplify-capital-structure-through-exchange-of-public-warrants-for-common-stock`	May 7, 2026	Exchange formula, warrant exercise price, and strategic rationale.
Amprius Q1 2026 financial-results release, `https://www.businesswire.com/news/home/20260506329974/en/Amprius-Technologies-Reports-First-Quarter-2026-Financial-Results-and-Recent-Business-Highlights`	May 6, 2026	Revenue, gross margin, net loss, adjusted EBITDA, order commentary, and 2026 revenue guidance.
Amprius Q1 2026 SEC exhibit, `https://www.sec.gov/Archives/edgar/data/1899287/000189928726000037/ampx-2026x05x06x8kex991.htm`	May 6, 2026	Primary filing support for Q1 financial release.
MarketBeat AMPX short-interest page, `https://www.marketbeat.com/stocks/NYSE/AMPX/short-interest/`	Last updated May 22, 2026; April 30 short-interest record	Reported short interest of 23,225,858 shares, 17.86% of float, and 2.7 days to cover.
Stooq daily quote CSV for `PCRX.US`, pulled June 1, 2026 at 12:03 ICT, `https://stooq.com/q/l/?s=pcrx.us&i=d`	May 29, 2026 market close	Candidate comparison price.
Pacira definitive proxy materials and investor release, `https://investor.pacira.com/node/19466/pdf`	April 28, 2026	Candidate comparison, June 9 annual-meeting catalyst.
Stooq daily quote CSV for `ENSC.US`, pulled June 1, 2026 at 12:03 ICT, `https://stooq.com/q/l/?s=ensc.us&i=d`	May 29, 2026 market close	Candidate comparison price.
Ensysce strategic-alternatives release, `https://www.nasdaq.com/press-release/ensysce-biosciences-initiates-review-strategic-alternatives-enhance-shareholder-value`	February 25, 2026	Candidate comparison, strategic-review evidence.

Section 17 Quality Gate

Question	Answer	Evidence
1. Is the mispricing specific?	yes	Warrant-overhang pricing versus known exchange terms and Q1 operating improvement.
2. Is there evidence beyond narrative?	yes	Current price, warrant exchange, Q1 financials, guidance, and short-interest data.
3. Is the positioning claim supported or clearly labeled as uncertain?	yes	Short interest is sourced; hedge composition is labeled unproven.
4. Is there a catalyst or plausible closing mechanism?	yes	Known warrant dilution, short-interest updates, and guidance recognition.
5. Is the downside case described honestly?	yes	Bottom case, valuation risk, dilution risk, and invalidation are explicit.
6. Is the strongest counterargument included?	yes	Valuation and residual SPAC-era dilution are the main counterargument.
7. Is the article useful even if the trade is not taken?	yes	It identifies the cap-table versus revenue-recognition tension and monitoring checklist.
8. Are all factual claims sourced or marked as unverified?	yes	Source table included; speculative short composition is labeled.
9. Does the article avoid hype?	yes	No hype words or promotional framing.
10. Does the headline match the actual evidence?	yes	The article is about warrants versus orders and operating evidence.
11. Does the article explain why this is the best opportunity right now?	yes	Opportunity Ranking and selected-opportunity text explain selection.
12. Does it explain why the asset can plausibly jump more than 5% soon?	yes	Move from $20.28 to $21.50 to $22.50 is tied to short-interest and cleanup triggers.
13. Does it identify what should surprise a sophisticated reader?	yes	Known dilution is smaller than physical exercise and coincides with Q1 inflection.
14. Does it include top, base, and bottom targets with probabilities adding to 100%?	yes	25%, 45%, and 30%.
15. Does the main article file include its Research Quality Scorecard in a dedicated section?	yes	Dedicated section included.
16. Are all reader-facing tables kept as Markdown tables in the main article file?	yes	All tables are Markdown.
17. Were optional table images requested and saved separately?	yes	Not requested, so no table images were created.
18. Is the illustration prompt included inline with a watermark requirement?	yes	Included below.
19. Does Best Trade Strategy include required fields?	yes	Direction, instrument, common stance, options stance, TP, SL, timeline, risks, do-not-trade conditions, monitoring checklist, and live price are included.
20. If technical signals are used, are they only timing inputs?	yes	Technical levels are used as risk and price markers, not as the thesis.
21. Unless geography was unscoped, did research screen U.S., Japan, broader Asia, Europe / UK?	yes	User explicitly scoped to U.S. market long, so non-U.S. lanes were not required.
22. If Japan was used, was the Japan small/mid-cap <= JPY 800 preference followed?	yes	Japan was not in scope.
23. If live Substack finish was requested, was it completed and logged?	yes	Not requested.

Illustration Prompt

Realistic, high-value, high-end elite, beautiful master image for The Mispricing Desk: a precision-engineered silicon battery cell on a dark institutional trading desk, half-lit by cool blue laboratory light and half-covered by translucent old SPAC warrant certificates dissolving into measured common-share blocks. In the background, a muted order book shows crowded short positions compressing while a clean aerospace drone battery module sits in sharp focus. Mood: skeptical, surgical, expensive, Bloomberg Markets cover quality, not promotional. Palette: graphite black, brushed steel, electric cyan, restrained amber highlights. Composition should visually express the tension between known warrant dilution and real defense/customer demand. Include a subtle but clear watermark/text reading "The Mispricing Desk" etched into the desk edge.